Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00272779 · ClinicalTrials.gov registry record · Phase 3
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,057
- Enrollment target
NCT00272779: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00272779 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,057 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00272779, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,057 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and antiviral effects of atazanavir (ATV) plus ritonavir (RTV) versus a combination drug of lopinavir (LPV) plus RTV. A combination drug containing tenofovir (TDF) and emtricitabine (FTC) will also be taken by participants in both arms.
Primary Outcome
HIV RNA \< 50 c/mL is the most stringent measure of viral suppression (lowest threshold of assay) and indicates that a participant responded to treatment.
Interventions
- DRUG ATV
- DRUG RTV
- DRUG Tenofovi-Emtricitabine (TDF/FTC) tablet
- DRUG LPV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,057 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
What the finished NCT00272779 record still lists
NCT00272779 is an interventional study that assigns participants to a tested intervention. Its 1,057 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% higher).
The record links to 0 conditions, and to 4 interventions - of which ATV is the first listed.
NCT00272779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00272779 about?
NCT00272779 is a clinical study titled "BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada". The purpose of this study is to evaluate the safety, tolerability and antiviral effects of atazanavir (ATV) plus ritonavir (RTV) versus a combination drug of lopinavir (LPV) plus RTV. A combination drug containing tenofovir (TDF) and emtricitabine (FTC) will also be taken by participants in both arm...
What is the current status of trial NCT00272779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,057 participants. The study started on 2005-11. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00272779?
The interventions under investigation include: ATV (DRUG), RTV (DRUG), Tenofovi-Emtricitabine (TDF/FTC) tablet (DRUG), LPV (DRUG).
Who is sponsoring clinical trial NCT00272779?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00272779's enrollment target sits among peer trials
1,057 276th of 2000 higher than 1,724 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07018869 · 1,057 participants · Phase 3
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- NCT03588286 · 1,058 participants · NA
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
- NCT03242642 · 1,056 participants · NA
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
- NCT04372108 · 1,056 participants
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia